TCT 2025: Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years, PARTNER-3 Trial Findings
The Medical Dialogues Bureau reports from the TCT Conference 2025 in San Francisco, USA.
At 7 years of follow-up, TAVR with the SAPIEN 3 valve showed comparable clinical outcomes, valve durability, and survival to SAVR in patients with severe symptomatic aortic stenosis at low surgical risk, according to the PARTNER 3 trial presented by Dr. Leon at TCT 2025 and published in The New England Journal of Medicine.
The PARTNER 3 trial, conducted across multiple international centers, is the largest randomized study comparing TAVR and SAVR in low-risk patients. The study enrolled 1,000 participants (mean age 73 years, 69% males) with severe symptomatic aortic stenosis and a Society of Thoracic Surgeons (STS) score below 4%.
Author summary: TAVR shows comparable outcomes to SAVR at 7 years.
More News
- Science Must Guide Policy on Protein Hydrolysate Biostimulants
- Two years later, no closure for family of missing Ghanaian fisheries observer
- New guidance on emergency authorisations of pesticides explained
- Action across the nation to ban greyhound racing
- Government gridlock cannot shut down the American farmer